Kurdish Studies
August 2024
Volume: 12, No: 04, pp 1899 - 1904
ISSN: 2051-4883 (Print) | ISSN 2051-4891 (Online)
www.KurdishStudies.net

DOI: 10.69980/ks.v12i4.4099

Molecular Mechanisms of Antibiotic Resistance in Bacteria: An Integrated Approach of Pharmacological Interventions, Microbiological Insights, Physiological Factors, and Clinical Strategies

DR. Sudhair Abbas Bangash*[1] Saira Rehman[2] Rana Muhammad Kamran Shabbir[3] Syeda Aaliya Shehzadi[4] Rida Fatima Saeed[5] Muhammad Farhan Siddiq Rao[6]

[1]Faculty of Life Science, Department of Pharmacy, Sarhad University of science and information technology, Peshawar, Pakistan. sudhair.fls@suit.edu.pk
[2]Faculty of Pharmaceutical Sciences, Pharmacognosy Department, Lahore University of Biological and Applied Sciences, Lahore, Pakistan
[3]Department of Zoology, Division of Science and Technology, University of Education Lahore, Punjab Pakistan
[4]Sulaiman Bin Abdullah Aba Al-Khail-Centre for Interdisciplinary Research in Basic Sciences (SA-CIRBS), International Islamic University, Islamabad-44000, Pakistan
[5]Department of Biological Sciences, National University of Medical Sciences, Rawalpindi rida.saeed@numspak.edu.pk; rida.saeed@hotmail.co.uk
[6] (IMBB) institute of molecular Biology and Biotechnology BAHAUDDIN ZAKARIYA University Multan

Abstract
Background:A major risk to world health is antibiotic resistance in bacteria, which is caused by both the overuse of antibiotics and the creation of resistant strains. Developing successful preventative and treatment methods requires an understanding of the clinical variables and molecular processes underlying resistance.
Objective: This study's goals were to clarify the molecular processes of antibiotic resistance in bacterial isolates and assess integrated techniques that include pharmacological treatments, microbiological understanding, physiological considerations, and clinical tactics for efficient management.
Methodology: Over the course of two years, 500 bacterial isolates from clinical samples, including blood, urine, wound swabs, and respiratory secretions, were used in this cross-sectional investigation. Resistance mechanisms were identified using PCR, sequencing, and antibiotic susceptibility testing; clinical relationships were evaluated using logistic regression. Chi-square tests were used to assess the relationships between resistance mechanisms and clinical variables, while descriptive statistics were used to describe patient demographics and resistance patterns. P-values less than 0.05 were regarded as statistically significant.
Results: Of the 500 bacterial isolates, 51.00% were Gram-negative and 49.00% were Gram-positive. Gram-negative isolates had the highest prevalence of resistance to penicillins (78.43%) and cephalosporins (82.35%), whilst the most common resistance mechanisms were β-lactamases (78.43%) and efflux pumps (62.75%). Chi-square tests revealed a substantial correlation ($p < 0.001$) between antibiotic usage history (72.00%), length of hospital stay (68.00%), and comorbidities (76.00%) and resistance mechanisms. Comorbidities, length of hospital stay, and history of antibiotic usage were shown to be significant predictors of resistance using logistic regression analysis.
Conclusion: The research emphasizes how crucial molecular mechanisms like β-lactamases and efflux pumps are to bacterial resistance. To reduce resistance and enhance patient outcomes, effective antibiotic stewardship and focused treatments targeting clinical variables are crucial.

Keywords: Antibiotic resistance, molecular mechanisms, pharmacological interventions, clinical strategies, bacterial isolates.

Introduction

Bacterial antibiotic resistance has become a major worldwide health concern that jeopardizes the efficacy of contemporary therapy [1]. Antibiotics have transformed healthcare since the discovery of penicillin, saving millions of lives [2]. But because of their extensive and often improper usage, resistant bacterial species have proliferated, endangering public health [3]. The urgent need for creative and comprehensive solutions is highlighted by the World Health Organization's (WHO) recognition of antibiotic resistance as one of the top ten worldwide public health problems [4].

A complex problem with genetic, biochemical, physiological, and environmental components, bacterial resistance is not a single occurrence [5]. To avoid the effects of antibiotics, bacteria use a wide range of strategies, such as biofilm development, target site alteration, efflux pump activation, and the synthesis of degrading enzymes [6]. Selective environmental constraints, horizontal gene transfer, and genetic mutations all play a complex role in regulating these processes [7]. Bacterial survival following antibiotic treatment is also influenced by physiological elements as metabolic dormancy and adaptive stress responses [8].

The resistance issue is made worse by clinical variables such inadequate treatment plans, antibiotic abuse, and imprecise diagnosis, which add to these biological complexity [9]. To successfully address antibiotic resistance, an integrated strategy is required due to the interaction between microbiological, pharmacological, and clinical factors [10]. Even while our knowledge

of the processes of bacterial resistance is expanding, current therapies frequently overlook how these variables are interrelated, which results in significant gaps in management and preventive measures [11].
By combining knowledge from pharmacology, microbiology, physiology, and clinical practice, this article seeks to close these gaps. This study aims to provide a comprehensive framework for addressing antibiotic resistance by investigating the molecular processes behind resistance and assessing novel pharmacological therapies in addition to microbiological and therapeutic approaches.

Objective
This study's goals were to clarify the molecular processes of antibiotic resistance in bacterial isolates and assess integrated techniques that include pharmacological treatments, microbiological understanding, physiological considerations, and clinical tactics for efficient management.

Methodology
Study Design and Setting
This cross-sectional study was conducted at the HMC, over a period of two years, from January 2022 to December 2023.

Inclusion and Exclusion Criteria
Bacterial isolates from clinical samples (blood, urine, wound swabs, and respiratory secretions) of patients who were 18 years of age or older and had been diagnosed with bacterial illnesses during the research period met the inclusion criteria. To evaluate the development of resistance, patients who had received antibiotic therapy during the two weeks previous to sample collection were included. Samples contaminated with various microbial species, fungal isolates, and patients with inadequate clinical data for analysis were among the exclusion criteria.

Sample Size
The sample size for this study was determined using Cochran's formula, $n = Z^2 \times p \times (1-p)/e^2$, where Z is the *Z*-score corresponding to a 95% confidence level (1.96), p is the estimated prevalence of antibiotic resistance based on prior studies at hospital (assumed as 50% for maximum variability), and e is the margin of error (5%, or 0.05). Based on this calculation, a total of 500 bacterial isolates were included in the study, ensuring adequate statistical power to identify significant patterns and trends in antibiotic resistance mechanism.

Data Collection
Standard microbiological methods, such as Gram staining, biochemical testing, and automated identification systems, were used to cultivate and identify the bacterial isolates. Following the recommendations set out by the Clinical and Laboratory Standards Institute (CLSI), antibiotic susceptibility was assessed using the Kirby-Bauer disk diffusion technique and minimum inhibitory concentration (MIC) tests. Polymerase chain reaction (PCR) and sequencing were used to examine molecular mechanisms of resistance, including the existence of resistance genes and efflux pumps. Clinical information was extracted from hospital records, including patient demographics, history of antibiotic use, and clinical results.

Statistical Analysis
SPSS software (version 26.0) was used to analyze the data. Patient demographics and resistance patterns were compiled using descriptive statistics. Resistance predictors were found using logistic regression, and correlations between resistance mechanisms and clinical variables were assessed using chi-square tests. P-values less than 0.05 were deemed statistically significant.

Results
The distribution of bacterial isolates according to sample source and Gram staining is shown in Figure 1. In total, 245 isolates, or 49.00% of the isolates, were Gram-positive, and 255 isolates, or 51.00%, were Gram-negative. Gram-positive bacteria made up 53.33% of blood samples, whereas Gram-negative bacteria made up 46.67%. 53.85% of urine samples were Gram-negative, whereas 46.15% were Gram-positive. Five out of ten wound samples were Gram-positive, and fifty percent were Gram-negative. Gram-positive bacteria made up 45.45% of respiratory secretions, whereas Gram-negative bacteria made up 54.55%.



Figure 1: Distribution of Bacterial Isolates by Sample Source and Gram Staining

Gram-positive and Gram-negative bacterial isolates' patterns of antibiotic resistance are shown in Table 1. Tetracycline resistance was the lowest among Gram-positive isolates (38.78%) while cephalosporin resistance was the greatest (57.14%). Resistance to cephalosporins (82.35%) and penicillins (78.43%) was most common among Gram-negative isolates.

Table 1: Antibiotic Resistance Patterns by Bacterial Isolate

Antibiotic Class		Resistant Bacteria (n; %)	Susceptible Bacteria (n; %)	Total Bacterial Isolates (n)
Gram-Positive	Penicillins	120 (49.00)	125 (51.00)	245
	Cephalosporins	140 (57.14)	105 (42.86)	
	Tetracyclines	95 (38.78)	150 (61.22)	
Gram-Negative	Penicillins	200 (78.43)	55 (21.57)	255
	Cephalosporins	210 (82.35)	45 (17.65)	
	Tetracyclines	175 (68.63)	80 (31.37)	

The molecular mechanisms of resistance found in both Gram-positive and Gram-negative bacterial isolates are shown in Figure 2. Beta-lactamases predominated in both Gram-positive (49.00%) and Gram-negative (78.43%) isolates, while efflux pumps were more prevalent in Gram-negative isolates (62.75%). Additionally, Gram-negative isolates had higher rates of target site alterations and biofilm development (70.59% and 74.51%, respectively).



Figure 2: Molecular Mechanisms of Resistance Detected

The correlation between clinical variables and resistance mechanisms, including biofilm development, target site alterations, beta-lactamases, and efflux pumps, is shown in Table 2. All resistance mechanisms showed strong correlations with antibiotic usage history, with efflux pumps showing 72.00%, beta-lactamases 84.00%, and target site alterations 76.00%. Significant correlations were also found between hospital stay length and comorbidities, especially with biofilm development (52.00% and 48.00%, respectively) and beta-lactamases (80.00% and 76.00%, respectively).

Table 2: Association of Resistance Mechanisms with Clinical Factors

Clinical Factor	Efflux Pumps (n; %)	Beta-lactamases (n; %)	Target Site Modifications (n; %)	Biofilm Formation (n; %)
Antibiotic Use History	180 (72.00)	210 (84.00)	190 (76.00)	150 (60.00)
Age	150 (60.00)	180 (72.00)	160 (64.00)	140 (56.00)
Hospital Stay Duration	170 (68.00)	200 (80.00)	170 (68.00)	130 (52.00)
Comorbidities	140 (56.00)	190 (76.00)	150 (60.00)	120 (48.00)

The clinical results linked to resistance patterns are shown in Table 3. Compared to 20.00% of susceptible individuals, 72.00% of resistant bacterial patients had treatment failure. In 68.00% of resistant patients and 24.00% of vulnerable individuals, extended hospital stays were noted. 60.00% of resistant patients had higher mortality than 16.00% of susceptible patients, and 56.00% of resistant patients had complications as opposed to 12.00% of susceptible patients.

Table 3: Clinical Outcomes Associated with Resistance Patterns

Clinical Outcome	Resistant Bacteria (n; %)	Susceptible Bacteria (n; %)	Total Patients (n)
Treatment Failure	180 (72.00)	50 (20.00)	250
Prolonged Hospital Stay	170 (68.00)	60 (24.00)	230
Increased Mortality	150 (60.00)	40 (16.00)	200
Complications	140 (56.00)	30 (12.00)	170

The findings of chi-square tests evaluating the relationships between resistance mechanisms and clinical characteristics are shown in Table 4. The resistance mechanisms (efflux pumps, beta-lactamases, target site alterations, and biofilm formation) were statistically significantly associated with all clinical parameters, including age, comorbidities, length of hospital stay, and history of antibiotic usage, with p-values < 0.001 for each factor.

Table 4: Chi-square Tests for Associations Between Resistance Mechanisms and Clinical Factors

Clinical Factor	Efflux Pumps	Beta-lactamases	Target Site Modifications	Biofilm Formation	Chi-square Value (χ^2)	p-value (< 0.05)
Antibiotic Use History	72.00	84.00	76.00	60.00	45.67	< 0.001
Age	60.00	72.00	64.00	56.00	32.89	< 0.001
Hospital Stay Duration	68.00	80.00	68.00	52.00	40.12	< 0.001
Comorbidities	56.00	76.00	60.00	48.00	35.45	< 0.001

The results of logistic regression, which reveal resistance mechanism predictors, are shown in Table 5. History of antibiotic usage was shown to be a significant predictor of target site alterations (OR = 3.50), beta-lactamases (OR = 4.00), and efflux pumps (OR = 3.50). The length of hospital stay was a predictor of biofilm development (OR = 3.00) and efflux pumps (OR = 2.80). Beta-lactamases (OR = 3.20) and target site alterations (OR = 2.80) were predicted by comorbidities, and biofilm development was likewise linked to comorbidities (OR = 2.50). Strong statistical significance was shown by all predictors' p-values being less than 0.001.

Table 5: Logistic Regression Identified Predictors of Resistance

Resistance Mechanism	Predictors	Odds Ratio (OR)	95% Confidence Interval (CI)	p-value (< 0.05)
Efflux Pumps	Antibiotic Use History	3.50	2.50 – 4.80	< 0.001
	Hospital Stay Duration	2.80	1.90 – 3.90	< 0.001
Beta-lactamases	Antibiotic Use History	4.00	3.00 – 5.50	< 0.001
	Comorbidities	3.20	2.20 – 4.30	< 0.001
	Age	3.50	2.50 – 4.80	< 0.001

Target Site Modifications	Comorbidities	2.80	1.90 – 3.90	< 0.001
Biofilm Formation	Hospital Stay Duration	3.00	2.00 – 4.00	< 0.001
	Comorbidities	2.50	1.80 – 3.20	< 0.001

Discussion

The findings of this study provide critical new insights into the clinical factors related to bacterial resistance in the clinical isolates as well as the molecular mechanisms responsible for antibiotic resistance. Out of 500 bacterial isolates that were screened, 245 (49.00%) were Gram-positive and 255 (51.0%) were Gram-negative. This distribution is similar to that shown in other studies which found variable amounts of Gram positive to Gram negative infections in differing clinical environments [12]. Our findings show the predominance of Gram-negative causative agents of infections, particularly from urine and respiratory secretions, consistent with other research demonstrating a higher incidence of Gram-negative bacteria in hospital-acquired infections [13].

Gram-negative isolates showed the highest antimicrobial resistance rates against cephalosporins (82.35%) and penicillins (78.43%) according to our analysis of the antibiotic resistance patterns. **Cephalosporin** resistance was found in 57.14% of Gram-positive isolates, while tetracycline resistance was found in 38.78%. These resistance patterns align with previous research that found that the most prevalent resistance targets in both Gram-positive and Gram-negative bacteria were β-lactam drugs [14]. Furthermore, our findings regarding cephalosporin resistance in Gram-negative isolates are much greater than those of earlier studies, highlighting the increasing threat presented by bacteria that produce extended-spectrum β-lactamase (ESBL) [15].

In 62.75% of Gram-negative isolates and 36.73% of Gram-positive isolates, efflux pumps were shown to be a major resistance mechanism. This finding is in line with earlier research showing the important role efflux systems play in multidrug resistance [16]. Both Gram-positive (49.00%) and Gram-negative (78.43%) isolates produced a lot of beta-lactamase, which supports earlier research that connected β-lactamase genes, including blaCTX-M, to resistance to β-lactam drugs [17]. Our findings also reveal significant levels of target site changes (70.59% in Gram-negative isolates), which is in line with earlier research that shown that fluoroquinolone-resistant organisms often had mutations in genes like gyrA and parC [18].

Clinical characteristics and resistance mechanisms were strongly correlated, especially with history of antibiotic usage. The research found that 76.00% of isolates with target site alterations, 84.00% with β-lactamases, and 72.00% with efflux pumps had previously used antibiotics. These results are in line with other studies that showed past exposure to antibiotics is a major risk factor for the emergence of resistance mechanisms [19]. According to studies, extended hospital stays increase the likelihood of biofilm development and the transmission of resistant bacteria [20]. Similarly, β-lactamase production and biofilm formation were substantially correlated with hospital stay length and comorbidities.

All things considered, the study's findings support our understanding of the molecular causes of antibiotic resistance and highlight the need of focused interventions, such as stewardship initiatives, to slow the development of resistance. These results advance our knowledge of the intricate interactions between resistance mechanisms and clinical variables, which is essential for creating efficient care plans.

Study Strength and Limitations

This study's merits include its thorough methodology, which combines clinical, microbiological, and molecular aspects to investigate antibiotic resistance in a wide range of bacterial isolates. Significant patterns in resistance mechanisms and clinical correlations may be found because to the statistical power provided by the high sample size of 500 isolates. Furthermore, the credibility of the results was increased by the use of sophisticated molecular methods like PCR and sequencing, which offered in-depth understanding of resistance mechanisms. One of the study's drawbacks, however, is its cross-sectional design, which makes it more difficult to determine causal correlations. Additionally, the use of hospital-based samples could limit the generalizability to illnesses acquired in the community. Additional limitations that could affect the study's wider application include the possibility of overlooking non-cultivable resistant strains and the absence of longitudinal data to monitor changes over time.

Conclusion

The molecular processes of antibiotic resistance in bacterial isolates are clarified by this work, which emphasizes the crucial roles of β-lactamases, efflux pumps, and target site changes, especially in Gram-negative bacteria. The significance of integrated methods to fight resistance is shown by the substantial correlations found between resistance mechanisms and clinical characteristics such comorbidities, length of hospital stay, and history of antibiotic usage. In order to prevent the development of resistant bacteria and guarantee efficient clinical care, our results highlight the need of focused interventions, such as antibiotic stewardship initiatives and enhanced diagnostic procedures.

References

1. Chinemerem Nwobodo D, Ugwu MC, Oliseloke Anie C, Al-Ouqaili MT, Chinedu Ikem J, Victor Chigozie U, Saki M. Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. Journal of clinical laboratory analysis. 2022 Sep;36(9):e24655. https://doi.org/10.1002/jcla.24655.
2. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: A narrative review. Pharmaceuticals. 2023 Nov 15;16(11):1615. https://doi.org/10.3390/ph16111615.

3. Serwecińska L. Antimicrobials and antibiotic-resistant bacteria: a risk to the environment and to public health. Water. 2020 Nov 25;12(12):3313. https://doi.org/10.3390/w12123313.
4. Aljeldah MM. Antimicrobial resistance and its spread is a global threat. Antibiotics. 2022 Aug 9;11(8):1082. https://doi.org/10.3390/antibiotics11081082.
5. Belay WY, Getachew M, Tegegne BA, Teffera ZH, Dagne A, Zeleke TK, Abebe RB, Gedif AA, Fenta A, Yirdaw G, Tilahun A. Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: A review. Frontiers in Pharmacology. 2024 Aug 16;15:1444781. https://doi.org/10.3389/fphar.2024.1444781.
6. Blanco P, Hernando-Amado S, Reales-Calderon JA, Corona F, Lira F, Alcalde-Rico M, Bernardini A, Sanchez MB, Martinez JL. Bacterial multidrug efflux pumps: much more than antibiotic resistance determinants. Microorganisms. 2016 Feb 16;4(1):14. https://doi.org/10.3390/microorganisms4010014.
7. Hossain AZ, Chowdhury AM. Understanding the evolution and transmission dynamics of antibiotic resistance genes: a comprehensive review. Journal of Basic Microbiology. 2024 Oct;64(10):e2400259. https://doi.org/10.1002/jobm.202400259.
8. Grant SS, Hung DT. Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response. Virulence. 2013 May 15;4(4):273-83. https://doi.org/10.4161/viru.23987.
9. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: A narrative review. Pharmaceuticals. 2023 Nov 15;16(11):1615. https://doi.org/10.3390/ph16111615.
10. Hernando-Amado, S., Coque, T.M., Baquero, F. *et al.* Defining and combating antibiotic resistance from One Health and Global Health perspectives. *Nat Microbiol* 4, 1432–1442 (2019). https://doi.org/10.1038/s41564-019-0503-9.
11. Puri B, Vaishya R, Vaish A. Antimicrobial resistance: Current challenges and future directions. Medical Journal Armed Forces India. 2024 Sep 19. https://doi.org/10.1016/j.mjafi.2024.07.006.
12. Kakoullis L, Papachristodoulou E, Chra P, Panos G. Mechanisms of antibiotic resistance in important gram-positive and gram-negative pathogens and novel antibiotic solutions. Antibiotics. 2021 Apr 10;10(4):415. https://doi.org/10.3390/antibiotics10040415.
13. Mamishi, S., Mahmoudi, S., Naserzadeh, N., Hosseinpour Sadeghi, R., Haghi Ashtiani, M. T., Bahador, A., … Pourakbari, B. (2019). Antibiotic resistance and genotyping of gram-negative bacteria causing hospital-acquired infection in patients referred to Children's Medical Center. Infection and Drug Resistance, 12, 3377–3384. https://doi.org/10.2147/IDR.S195126.
14. Pitout JD, Sanders CC, Sanders Jr WE. Antimicrobial resistance with focus on β-lactam resistance in gram-negative bacilli. The American journal of medicine. 1997 Jul 1;103(1):51-9. https://doi.org/10.1016/S0002-9343(97)00044-2.
15. Rupp, M.E., Fey, P.D. Extended Spectrum β-Lactamase (ESBL)-Producing Enterobacteriaceae. *Drugs* 63, 353–365 (2003). https://doi.org/10.2165/00003495-200363040-00002.
16. Aeschlimann JR. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy: The Journal of human pharmacology and drug therapy. 2003 Jul;23(7):916-24. https://doi.org/10.1592/phco.23.7.916.32722.
17. Ojdana D, Sacha P, Wieczorek P, Czaban S, Michalska A, Jaworowska J, Jurczak A, Poniatowski B, Tryniszewska E. The Occurrence of blaCTX-M, blaSHV, and blaTEM Genes in Extended-Spectrum β-Lactamase-Positive Strains of Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis in Poland. International Journal of Antibiotics. 2014;2014(1):935842. https://doi.org/10.1155/2014/935842.
18. Mirzaii M, Jamshidi S, Zamanzadeh M, Marashifard M, Hosseini SA, Haeili M, Jahanbin F, Mansouri F, Darban-Sarokhalil D, Khoramrooz SS. Determination of gyrA and parC mutations and prevalence of plasmid-mediated quinolone resistance genes in Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infection in Iran. Journal of Global Antimicrobial Resistance. 2018 Jun 1;13:197-200. https://doi.org/10.1016/j.jgar.2018.04.017.
19. Uddin TM, Chakraborty AJ, Khusro A, Zidan BR, Mitra S, Emran TB, Dhama K, Ripon MK, Gajdács M, Sahibzada MU, Hossain MJ. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. Journal of infection and public health. 2021 Dec 1;14(12):1750-66. https://doi.org/10.1016/j.jiph.2021.10.020.
20. Assefa, M., & Amare, A. (2022). Biofilm-Associated Multi-Drug Resistance in Hospital-Acquired Infections: A Review. Infection and Drug Resistance, 15, 5061–5068. https://doi.org/10.2147/IDR.S379502